Cardiovascular Medicine webinar — Reperfusion therapy for STEMI: A case for the pharmacoinvasive approach even in the USA

In this Cardiovascular Medicine webinar, Reperfusion therapy for ST-elevated myocardial infarction (STEMI): A case for the pharmacoinvasive approach even in the USA, Mayo Clinic cardiology experts Bernard J. Gersh, M.B., Ch.B., D.Phil., and Mandeep Singh, M.D., focus on the impact of early reperfusion on infarct size and outcomes with an emphasis on a systems approach in communities that do not have a percutaneous coronary intervention (PCI)-capable catheterization laboratory and consequently rely on rapid transport to a referral hospital with the requisite facilities. The advantages and disadvantages of thrombolysis followed by transport (the "drip and ship" or pharmacoinvasive approach) are discussed, as are barriers to optimizing this therapeutic strategy.

For more information or to refer a patient, visit Mayo Clinic Medical Professionals — Cardiovascular Diseases.


March 12, 2021

Created by

Mayo Clinic

Related Presenters

Mandeep Singh, MD

Mandeep Singh, MD

Interventional Cardiologist

View full profile